港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

禮邦醫藥-B

32.660

+0.2000.62%

成交量：9.63萬

成交額：309.34萬

市值：113.66億

市盈率：-10.63

高：32.600

開：31.140

低：31.140

收：32.460

52周最高：46.820

52周最低：22.720

股本：3.48億

香港流通股本：2.36億

量比：0.72

換手率：0.04%

股息：- -

股息率：- -

每股收益(LYR):-3.071

淨資產收益率：--

總資產收益率：-33.01%

市淨率：19.37

市盈率(LYR):-10.63

市銷率: 319.02

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

財報前瞻｜禮邦醫藥-B本季度預測數據未披露，機構觀點待明朗

獲納入恒生綜指禮邦醫藥-B(09637.HK)有望躋身港股通

禮邦醫藥-B：Tencent Holdings Limited增持，好倉比例升至10.0%

禮邦醫藥-B（09637）臨時股東會通過審計師委任及股份發行、回購授權

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/09637"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","market":"HK","secType":"STK","nameCN":"禮邦醫藥-B","latestPrice":32.66,"timestamp":1787634373652,"preClose":32.46,"halted":0,"volume":96300,"delay":0,"changeRate":0.0061614294516326475,"floatShares":236000000,"shares":348000000,"eps":-3.071284,"marketStatus":"交易中","change":0.2,"latestTime":"08-25 13:07:38","open":31.14,"high":32.6,"low":31.14,"amount":3093434,"amplitude":0.044978,"askPrice":32.66,"askSize":500,"bidPrice":32.52,"bidSize":400,"shortable":0,"etf":0,"ttmEps":-2.384,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1787645400000},"marketStatusCode":2,"adr":0,"listingDate":1782662400000,"exchange":"SEHK","adjPreClose":32.46,"openAndCloseTimeList":[[1787621400000,1787630400000],[1787634000000,1787644800000]],"volumeRatio":0.722908,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","floatShares":236000000,"roa":"-33.01%","roe":"--","lyrEps":-3.071284,"volumeRatio":0.722908,"shares":348000000,"dividePrice":0,"high":32.6,"amplitude":0.044978,"preClose":32.46,"low":31.14,"week52Low":22.72,"pbRate":"19.37","psRate":"319.02","week52High":46.82,"institutionHeld":0,"latestPrice":32.66,"committee":-0.111111,"eps":-3.071284,"divideRate":0,"volume":96300,"delay":0,"ttmEps":-2.384,"open":31.14,"prevYearClose":22.6,"prevWeekClose":33.12,"prevMonthClose":27.24,"prevQuarterClose":45.92,"fiveDayClose":33.98,"twentyDayClose":27.86,"sixtyDayClose":22.6,"earningDate":1787673600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09637\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"09637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1786723200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09637","date":"2026-08-21","current":-13.615772,"percent":0.342105,"low":-18.066068,"twenty":-13.077865,"median":-11.725167,"eighty":-10.931752,"high":-8.87585,"avg":-12.195851,"sd":1.7985,"marketCap":11255905890},"quantilePoints":[{"date":"2026-06-26","current":-8.87585,"twenty":-8.87585,"median":-8.87585,"eighty":-8.87585,"marketCap":7680660420},{"date":"2026-07-03","current":-11.883178,"twenty":-18.03155,"median":-11.883178,"eighty":-9.78101,"marketCap":10290725554},{"date":"2026-07-10","current":-12.164969,"twenty":-13.966639,"median":-11.847257,"eighty":-11.12129,"marketCap":10521825071},{"date":"2026-07-17","current":-10.947234,"twenty":-12.322489,"median":-11.455859,"eighty":-10.783874,"marketCap":9502268378},{"date":"2026-07-24","current":-11.320561,"twenty":-11.939536,"median":-11.377389,"eighty":-10.939493,"marketCap":9828526520},{"date":"2026-07-31","current":-10.642718,"twenty":-11.840073,"median":-11.194259,"eighty":-10.78337,"marketCap":9257574772},{"date":"2026-08-07","current":-12.743391,"twenty":-12.396338,"median":-11.399787,"eighty":-10.889159,"marketCap":11106370909},{"date":"2026-08-14","current":-13.03884,"twenty":-12.987078,"median":-11.462395,"eighty":-10.903987,"marketCap":11378252693},{"date":"2026-08-21","current":-12.870195,"twenty":-13.077865,"median":-11.725167,"eighty":-10.931752,"marketCap":11255905890}],"updateTime":1787613950997},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09637\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1158482414","title":"財報前瞻｜禮邦醫藥-B本季度預測數據未披露，機構觀點待明朗","url":"https://stock-news.laohu8.com/highlight/detail?id=1158482414","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1158482414?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 09:10","pubTimestamp":1787101826,"startTime":"0","endTime":"0","summary":"礼邦医药-B将于2026年08月26日发布最新季度财报，市场对关键指标共识尚未形成，投资者关注度集中在现金流与商业化推进节奏。由于未获得权威一致预期及公司层面的本季度前瞻披露，关于本季度的营收、毛利率、净利润或净利率、调整后每股收益的预测信息暂无可用数据。市场在本季度更关注期间费用率的变化轨迹，其中销售费用与研发费用的配置会直接影响利润端的弹性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜礼邦医药-B本季度预测数据未披露，机构观点待明朗","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661326717","title":"獲納入恒生綜指 禮邦醫藥-B(09637.HK)有望躋身港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2661326717","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661326717?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 19:26","pubTimestamp":1787311583,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","09939","09637","BK1161","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164312475","title":"禮邦醫藥-B：Tencent Holdings Limited增持，好倉比例升至10.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164312475","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164312475?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 17:11","pubTimestamp":1787303498,"startTime":"0","endTime":"0","summary":"Tencent Holdings Limited于2026年8月17日以每股均价32.3366港元买入礼邦医药-B股份3.10万股，涉资约100.24万港元。Tencent Holdings Limited此次增持前持有礼邦医药-B好仓2353.56万股，占比9.99%；增持后持股量为2356.66万股，好仓比例升至10.0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198136493","title":"禮邦醫藥-B（09637）臨時股東會通過審計師委任及股份發行、回購授權","url":"https://stock-news.laohu8.com/highlight/detail?id=1198136493","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198136493?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 18:22","pubTimestamp":1786702925,"startTime":"0","endTime":"0","summary":"8月14日，礼邦医药-B公布其于2026年8月14日举行的临时股东会投票结果，全部议案均获股东高票通过。此次会议共有348,365,531股具表决权股份获准参与投票，公司董事会成员全部以现场或电子方式出席会议。公告同时披露，截至EGM召开日，公司无任何库存股份或待注销的回购股份，亦不存在股东受限投票或需放弃投票的情形。截至公告日，礼邦医药-B董事会由4名执行董事、1名非执行董事及3名独立非执行董事组成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":17,"pageCount":1,"totalSize":67,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/09637\",params:#limit:6,delay:false,,,undefined,":[]}}